Vireo Growth (VREOF) Net Income towards Common Stockholders (2020 - 2026)

Vireo Growth (VREOF) reported Net Income towards Common Stockholders of -$22.5 million for Q1 2026, down 562.98% on a YoY basis from $4.9 million in Q1 2025, and up 33.39% sequentially from -$33.8 million in Q4 2025.

Vireo Growth (VREOF) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Vireo Growth (VREOF) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$22.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 562.98% year-over-year to -$22.5 million; the trailing twelve-month figure through Mar 2026 stood at -$49.8 million (down 384.51% YoY), and the FY2025 full-year result was -$81.5 million, down 598.32% from the prior year.
  • Net Income towards Common Stockholders advanced to -$22.5 million in Q1 2026, from -$33.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $4.9 million in Q1 2025 to a low of -$33.8 million in Q4 2025.
  • A 5-year average of -$5.3 million and a median of -$5.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Across the five-year window, Net Income towards Common Stockholders soared 176.72% in 2024 and sank 903.06% in 2025, its largest moves.
  • Tracing VREOF's Net Income towards Common Stockholders over 5 years: stood at -$9.3 million in 2022, then jumped by 138.44% to $3.6 million in 2023, then climbed by 17.77% to $4.2 million in 2024, then slumped by 903.06% to -$33.8 million in 2025, then soared by 33.39% to -$22.5 million in 2026.
  • Business Quant data shows VREOF's Net Income towards Common Stockholders at -$22.5 million in Q1 2026, -$33.8 million in Q4 2025, and $2.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 57.00 Mn
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn -22.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -22.50 Mn
Dec 31, 2025 -33.78 Mn
Sep 30, 2025 2.76 Mn
Jun 30, 2025 3.67 Mn
Mar 31, 2025 4.86 Mn
Dec 31, 2024 4.21 Mn
Sep 30, 2024 4.40 Mn
Jun 30, 2024 4.06 Mn
Mar 31, 2024 3.70 Mn
Dec 31, 2023 3.57 Mn
Sep 30, 2023 -5.73 Mn
Jun 30, 2023 -7.39 Mn
Mar 31, 2023 -8.47 Mn
Dec 31, 2022 -9.29 Mn
Sep 30, 2022 -9.57 Mn
Jun 30, 2022 -6.10 Mn
Mar 31, 2022 -17.68 Mn
Dec 31, 2021 -14.09 Mn
Sep 30, 2021 -6.84 Mn
Jun 30, 2021 -6.99 Mn